Ponatinib 15mg

The active substance of the composition is ponatinib. This pharmacological agent is intended for the treatment of patients with chronic myeloid leukemia, as well as acute lymphoblastic leukemia, which have a positive reaction to the presence of the Philadelphia chromosome.

Mechanism of action of the remedy

Ponatinib 15mg is a selective tyrosine kinase blocker. This protein compound is necessary for growth and reproduction of tumor cell elements. In addition, it was noted that in the treatment of chronic myeloid leukemia, this remedy had a particularly pronounced effect in case the malignant degenerated cells had a mutation of the T315I type.

Application Protocol

Ponatinib 15mg is available in a tablet form for oral usage. The standard dosage of the remedy is 45 mg (3 tablets), which is taken once a day. At the same time, it is prohibited to chew, dissolve in water or crush, but must be swallowed whole. Reception of Ponatinib 15mg does not depend on the time of food intake. Your treatment doctor determines the duration of therapy with this medication, but usually it is long enough and does not stop until a clinical response or a pronounced side effect develops.

Efficiency of taking

The efficacy of Ponatinib 15mg has been studied in several large-scale clinical trials. According to the data obtained in their course, the clinical response to varying degrees of this remedy caused in all patients, regardless of the presence or absence of the mutation T315I. A high level of clinical response to treatment with Ponatinib 15mg was observed in 54% of patients without T315I mutation and in more than 80% of patients with this mutation.

Contraindications

Ponatinib 15mg is not used if the patient has allergic reactions to any of the major or additional substances that make up the remedy.